Posted on 10/03/2003 9:48:28 AM PDT by kattracks
Total BS! There has been plenty of times people have said NO COMMENT and people like you call up to persecute them. Rush's answer has always been to wait till all of the information is in. I just love the way you demoncrats come here to bash Rush!
Great idea. As for your 'layer' question, I'd like 2 layers of Nigerian Yellow Cake Plamebe' with puree'd wilson sauce....please.
And you use National Enquirer for the truth?
If you don't like the facts, just sling sh#t, right?
Fox Reporter Orlando Salinas just reported that physicians they have consulted have told them that taking high doses of the narcotics Rush is alleged to have bought can cause HEARING LOSS
Is the picture becoming clear now?
Or is Fox News part of the "left-wing conspiracy" too?
You Rushbots are unbelievable.
MSNBC reported last hour that law enforcement sources involved in the case had confirmed to them that the Enquirer story tracked the case file very closely.
These days, Enquirer stories are carefully vetted by their media attorneys; the paper is probably more accurate on the whole than other national newspapers
So you admit not having a prescription? Or are you saying that the painkillers you were using were not prescription drugs?
Is the picture becoming clear now?
Or is Fox News part of the "left-wing conspiracy" too?
You Rushbots are unbelievable.
Why don't you use your own noodle instead of parroting someone else's garbage.
Oxycontin Side Effects / Oxycodone HCl
The safety of OxyContin® was evaluated in double-blind clinical trials involving 713 patients with moderate to severe pain of various etiologies. In open-label studies of cancer pain, 187 patients received OxyContin® in total daily doses ranging from 20 mg to 640 mg per day. The average total daily dose was approximately 105 mg per day. Serious adverse reactions which may be associated with OxyContin® (oxycodone hydrochloride controlled-release) tablet therapy in clinical use are those observed with other opioid analgesics, including respiratory depression, apnea, respiratory arrest, and (to an even lesser degree) circulatory depression, hypotension, or shock (see OXYCONTIN OVERDOSE). The non-serious adverse events seen on initiation of therapy with OxyContin® are typical opioid side effects. These events are dose-dependent, and their frequency depends upon the dose, the clinical setting, the patient s level of opioid tolerance, and host factors specific to the individual. They should be expected and managed as a part of opioid analgesia. The most frequent (>5%) include: constipation, nausea, somnolence, dizziness, vomiting, pruritus, headache, dry mouth, sweating, and asthenia. In many cases the frequency of these events during initiation of therapy may be minimized by careful individualization of starting dosage, slow titration, and the avoidance of large swings in the plasma concentrations of the opioid. Many of these adverse events will cease or decrease in intensity as OxyContin® therapy is continued and some degree of tolerance is developed. Clinical trials comparing OxyContin® with immediate-release oxycodone and placebo revealed a similar adverse event profile between OxyContin® and immediate-release oxycodone. The most common adverse events (>5%) reported by patients at least once during therapy were:
The following adverse experiences were reported in OxyContin® treated patients with an incidence between 1% and 5%. In descending order of frequency they were anorexia, nervousness, insomnia, fever, confusion, diarrhea, abdominal pain, dyspepsia, rash, anxiety, euphoria, dyspnea, postural hypotension, chills, twitching, gastritis, abnormal dreams, thought abnormalities, and hiccups. The following adverse reactions occurred in less than 1% of patients involved in clinical trials or were reported in post marketing experience: General: accidental injury, chest pain, facial edema, malaise, neck pain, pain. Opioid analgesics, including OxyContin®, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Oxycodone is metabolized in part to oxymorphone via cytochrome P450 2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs including amiodarone and quinidine as well as polycyclic antidepressants), such blockade has not yet been shown to be of clinical significance with this agent. Clinicians should be aware of this possible interaction, however. |
What does that mean?
Well now which is it? Does the NE article follow the investigation closely or does it not? The drug in the investigation is Oxycontin.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.